Fundraising FoxVersant Venture Capital — Full Portfolio
6 tracked investments · listed companies and verified rows first
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)
Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)Nextech InvestNSG VenturesRA Capital+4 more
858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways.
BiotechHealthtechSan Diego, US
Stafford Jeffrey(Executive Officer, Director)inJames Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)Joseph Leveque(Chief Medical Officer)
BoardMonal Mehta(Director)inAli Behbahani(Director)in
Board seatBradley J. BolzonClare Ozawa· per SEC Form D · $37.5M raise · filed Mar 2020
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.
BiotechDeep TechHealthtechZug, CH
Emmanuelle Charpentier(Founder)Samarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJames R. Kasinger(General Counsel and Secretary)inStephen Kennedy(Head of Technical Operations)inMegan Wherry Menner(Head of Human Resources)inNaimish Patel(Chief Medical Officer)in
Board seatBradley BolzonThomas Woiwode· per SEC Form D · $35M raise · filed Nov 2016
Co-investorsAvoro Capital AdvisorsCLI VenturesKhosla VenturesNew Enterprise Associates (NEA)SR One Capital ManagementVersant Ventures+2 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Board seatClare OzawaThomas Woiwode· per SEC Form D · $70.1M raise · filed Sep 2021
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.
AI & Machine LearningBiotechHealthtechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)inNewman Yeilding(Chief Medical Officer)in
Board seatJerel DavisThomas Woiwode· per SEC Form D · $70.3M raise · filed Feb 2023
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant VenturesRTW Investments L.P.TPG+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.